- A review by the Journal of Prevention of Alzheimer's Disease has found no evidence of data manipulation in a 2020 paper on Cassava Sciences' ( NASDAQ: SAVA ) Alzheimer's candidate simufilam.
- "We do not find convincing evidence of manipulation of data or intent to mislead, and therefore take no action regarding the published paper," the journal wrote to the company
- Cassava ( SAVA ) shares are up 17% in Thursday morning trading.
- "I'm hopeful that written pronouncements from neutral and independent science experts will help close the chapter of baseless attacks against our science," CEO Remi Barbier said.
- "At some point it becomes irrational for our detractors to repeat over and over again the same old tired mantra of data manipulation," he added.
- The company has been accused of research misconduct by several entities. Cassava has responded that they are baseless and are motivated by short sellers.
- Cassava is still awaiting the results of an investigation from The City University of New York on one of its own researchers who published positive results on simufilam that has come under scrutiny.
- In July, it was reported that the Department of Justice began a criminal probe into the company .
For further details see:
Cassava cleared of simufilam data manipulation by medical journal; shares rise 17%